SELLAS Life Sciences Group, Inc. (36)
Browse by Contract Category
Contracts
-
License Agreement effective as of March 31, 2022 by and between SELLAS Life Sciences Group, Inc. and GenFleet Therapeutics (Shanghai) Inc
(Filed With SEC on May 12, 2022)
-
Form of Warrant
(Filed With SEC on April 1, 2022)
-
First Amendment to Sublease dated December 6, 2021 between the Registrant and Riemer & Braunstein LLP
(Filed With SEC on March 31, 2022)
-
Change in Control Severance Agreement, dated December 14, 2021, between SELLAS Life Sciences Group, Inc and Dragan Cicic, M.D
(Filed With SEC on December 16, 2021)
-
Termination Agreement between the Registrant, The Henry M. Jackson Foundation, and the MD Anderson Cancer Center, dated February 4, 2021
(Filed With SEC on March 23, 2021)
-
Form of Placement Agent Agreement
(Filed With SEC on December 14, 2020)
-
Underwriting Agreement, dated March 31, 2022, by and among the Company and SVB Securities LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters named...
(Filed With SEC on April 1, 2022)
-
2021 Employee Stock Purchase Plan
(Filed With SEC on August 12, 2021)
-
Exclusive License Agreement by and among SELLAS, SLSG, and 3DMed, dated as of December 7, 2020
(Filed With SEC on January 28, 2021)
-
Form of Securities Purchase Agreement, dated as of December 13, 2020, by and among SELLAS Life Sciences Group, Inc. and the Investor
(Filed With SEC on December 14, 2020)
-
First Amendment to Amended and Restated Exclusive License Agreement between SLSG Limited LLC and Memorial Sloan Kettering Cancer Center, effective as of September 29, 2020
(Filed With SEC on November 13, 2020)
-
Form of Warrant
(Filed With SEC on August 4, 2020)
-
Form of Registration Rights Agreement
(Filed With SEC on August 4, 2020)
-
Form of Purchase Agreement
(Filed With SEC on August 4, 2020)
-
Sublease, effective June 5, 2020, by and between the Company and Reimer & Braunstein LLP
(Filed With SEC on June 11, 2020)
-
Employment Agreement by and between SELLAS Life Sciences Group, Inc. and Angelos Stergiou, effective July 1, 2019
(Filed With SEC on May 14, 2020)
-
Description of Securities
(Filed With SEC on March 13, 2020)
-
Form of Stock Option Grant Notice and Option Agreement under the 2019 Equity Incentive Plan
(Filed With SEC on March 13, 2020)
-
Form of Restricted Stock Unit Grant and Agreement under the 2019 Equity Incentive Plan
(Filed With SEC on March 13, 2020)
-
Form of Pre-Funded Warrant
(Filed With SEC on January 10, 2020)
-
Form of Securities Purchase Agreement, dated as of January 9, 2020, by and among SELLAS Life Sciences Group, Inc. and the Investor
(Filed With SEC on January 10, 2020)
-
Form of Investor Warrant
(Filed With SEC on January 10, 2020)
-
Form of Placement Agent Agreement
(Filed With SEC on January 10, 2020)
-
Amendment to Warrant to Purchase Common Stock
(Filed With SEC on January 7, 2020)
-
2019 Equity Incentive Plan
(Filed With SEC on November 14, 2019)
-
Equity Distribution Agreement, dated October 29, 2019, by and between SELLAS Life Sciences Group, Inc. and Maxim Group LLC
(Filed With SEC on October 31, 2019)
-
Amendment to Warrant Agreement
(Filed With SEC on July 9, 2019)
-
Form of Investor Agreement
(Filed With SEC on July 9, 2019)
-
Form of Pre-Funded Warrant
(Filed With SEC on June 18, 2019)
-
Warrant Agreement including form of accompanying Common Warrant, dated as of June 18, 2019, between the Company and Computershare
(Filed With SEC on June 18, 2019)
-
Underwriting Agreement dated June 14, 2019 between the Company and A.G.P./Alliance Global Partners, LLC
(Filed With SEC on June 18, 2019)
-
Form of Warrant Agreement, including Form of Common Warrant
(Filed With SEC on June 13, 2019)
-
Form of Pre-Funded Warrant
(Filed With SEC on June 13, 2019)
-
Form of Underwriting Agreement
(Filed With SEC on June 13, 2019)
-
Form of Warrant Exercise Agreement
(Filed With SEC on March 6, 2019)
-
Form of New Warrant
(Filed With SEC on March 6, 2019)